New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 9, 2014
09:11 EDTSQNM, MCK, BBBY, BIIB, ROVI, DG, YRCW, SGMO, QIHU, ICPT, JCP, FDO, MOn The Fly: Pre-market Movers
HIGHER: Macy's (M), up 6% after announcing cost reduction initiatives that include cutting 2,500 jobs and issuing FY14 EPS guidance that beat the consensus analyst estimate... Intercept (ICPT), up over 200% after announcing NASH primary endpoint met, FLINT trial stopped early... J.C. Penney (JCP), up 3% after upgraded at Piper Jaffray... McKesson (MCK), up 3.7% after making final offer for Celesio, increases price to EUR 23.50 per share... Sangamo (SGMO), up 14.3% after collaborating with Biogen (BIIB) for hemoglobinopathy treatment development... Sequenom (SQNM), up 10.6% after granted patent by European patent office... DOWN AFTER EARNINGS: Family Dollar (FDO), down 7.3%. Peer Dollar General (DG) down 2.4% in sympathy... Bed Bath & Beyond (BBBY), down 9%... Rovi (ROVI), down 3.4%. ALSO LOWER: Qihoo 360 (QIHU), down 4.5% after China Daily reported the company denied Alibaba's interested in investing... YRC Worldwide (YRCW), down 13% after Teamsters group says union contract extension may be defeated.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 >>
September 25, 2015
08:49 EDTBBBYBed Bath & Beyond shares attractive, says SunTrust
Subscribe for More Information
07:55 EDTBIIBBiogen, Sobi receive position opinion for Elocta from CHMP
Subscribe for More Information
07:32 EDTBIIBBiogen, Sobi receive positive CHMP opinion for Elocta for Hemophilia A
Biogen and Swedish Orphan Biovitrum AB received a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use for the marketing authorization of ELOCTA. ELOCTA is a recombinant factor VIII Fc fusion protein product for the treatment of hemophilia A that, if approved, would be the first hemophilia A treatment with prolonged circulation available in the European Union. The positive opinion was based on results from the pivotal, Phase 3 A-LONG clinical study, which examined the efficacy, safety and pharmacokinetics of rFVIIIFc in previously treated males 12 years of age and older with severe hemophilia A, and from the Phase 3 Kids A-LONG clinical study, which evaluated the efficacy and safety of rFVIIIFc in previously treated male children with hemophilia A under 12 years of age. The Committee's positive opinion is now referred to the EC, which grants marketing authorization for medicines in the EU. ELOCTA is the European trade name for rFVIIIFc, which is also known as ELOCTATE in the U.S., Canada, Australia, New Zealand and Japan, where it is approved for the treatment of hemophilia A. Commonly reported adverse drug reactions in the clinical studies were arthralgia, malaise, myalgia, headache and rash. Development of Factor VIII neutralizing antibodies may occur following administration of ELOCTA. Biogen and Sobi are collaboration partners in the development and commercialization of ELOCTA/ELOCTATE for hemophilia A. Last year, Sobi exercised its opt-in right to assume final development and commercialization of ELOCTA in the Sobi territories. Biogen leads development for ELOCTA/ELOCTATE, has manufacturing rights, and has commercialization rights in North America and all other regions in the world excluding the Sobi territories.
07:02 EDTSQNMSequenom sees FY15 revenue $127M-$131M, consensus $141.04M
Subscribe for More Information
06:35 EDTBBBYBed Bath & Beyond upgraded to Market Perform at Telsey Advisory
Subscribe for More Information
September 24, 2015
19:14 EDTBBBYOn The Fly: After Hours Movers
HIGHER AFTER EARNINGS: Jabil Circuit (JBL), up 9.6%... Nike (NKE), up 8%. ALSO HIGHER: Bellerophon Therapeutics (BLPH), up 92% after announcing "positive" data from its interim Phase 2 study of INOpulse... Reynolds American (RAI), up 1% after Bloomberg reported the company may sell $5B in assets to Japan Tobacco... Marvell (MRVL), up 5.15% after announcing a 17% global headcount reduction. LOWER AFTER EARNINGS: Pier 1 Imports (PIR), down 7.5%... Bed Bath & Beyond (BBBY), down 1%. ALSO LOWER: Internap (INAP), down 15.1% after cutting its FY15 revenue forecast... Emerge Energy Services (EMES), down 3.25% after withdrawing its distribution guidance due to "difficult market conditions."
16:23 EDTBBBYBed Bath & Beyond falls to fresh 52-week low after results
In the after hours session the shares are currently down 4% to $56.95. At that price next support is at $56.18 and then at $54.96. Resistance is at $58.28.
16:21 EDTBBBYBed Bath & Beyond announces new $2.5B share repurchase program
Subscribe for More Information
16:19 EDTBBBYBed Bath & Beyond sees FY15 EPS flat to up a mid-single digit, consensus $5.22
Subscribe for More Information
16:18 EDTBBBYBed Bath & Beyond sees Q3 EPS $1.14-$1.21, consensus $1.19
Comparable sales are modeled to increase between 1.0% and 3.0% for the third and fourth quarters of fiscal 2015.
16:17 EDTBBBYBed Bath & Beyond reports Q2 EPS $1.21, consensus $1.21
Subscribe for More Information
15:12 EDTBBBYBed Bath & Beyond September 59 weekly straddle priced for 5.3% movement
Subscribe for More Information
15:00 EDTBBBYNotable companies reporting after market close
Subscribe for More Information
14:07 EDTBBBYPride Brands recalls 13,900 Bed Bath & Beyond hammock stands
Pride Family Brands has recalled roughly 13,900 hammock stands sold under the Bed Bath & Beyond Destination Summer private label. The firm has received 13 reports of the stands' hooks bending or breaking, resulting in consumers falling to the ground and injuring various body parts. The stands were sold in Bed Bath & Beyond stores nationwide and online from March 2014 through July 2015 for approximately $100. Reference Link
September 23, 2015
15:05 EDTBBBYBed Bath & Beyond volatility elevated into Q2 and outlook
Bed Bath & Beyond September weekly call option implied volatility is at 92, October is at 37, November is at 30; compared to its 52-week range of 15 to 40, suggesting large near term price movement into the expected release of Q2 results on September 24.
10:24 EDTBIIBOptions with increasing implied volatility
Options with increasing implied volatility: SNCR PTCT SRPT AMZN CREE CMG ISRG QLIK SNKD BIIB JNPR
09:55 EDTBIIBActive calls on open: BIIB FCX X F INTC
Subscribe for More Information
09:33 EDTBIIBActive equity options trading on open: AAPL BBRY BIDU BIIB
Subscribe for More Information
07:08 EDTJCPJ.C. Penney names John Tighe chief merchant
Subscribe for More Information
06:37 EDTJCPJ.C. Penney seeks new chief merchant to replace Sweney, WSJ reports
J.C. Penney is searching for a new chief merchant, The Wall Street Journal reports, citing sources familiar with the matter. The new executive would replace Elizabeth Sweney, who has held the role since 2012. It is unclear whether the new chief merchant would be an internal or external candidate, but one source says that an announcement relating to the role will be made "early Wednesday morning." Reference Link
1 | 2 | 3 | 4 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use